Developing countries face disastrous healthcare setbacks, hunger and huge international debt as covid-19’s ‘final wave’
Lancet 2012; 380: 611–19
Series: Hypertension 3
Received: 16/11/2013 - Accepted: 23/03/2014 - Published: 27/07/2014
BMJ VOLUME 322 24 FEBRUARY 2001 bmj.com
How has funding to developing countries for health improvement changed in the wake of the global financial crisis? The question is vital for policy making, planning, and advocacy purposes in donor and recipient countries alike. We measured the total amount of financial and in-kind assistance that fl...owed from both public and private channels to improve health in developing countries during the period 1990–2011
more
Recommendations for step-wise implementation
Polymerase Chain Reaction (PCR) has significantly helped in early diagnosis and commencement of specific interventions for diseases control. It also plays a critical role in understanding the disease epidemiology and unraveling the transmission dynamics of the disease. This manual intends to p...rovide primary guidelines to assist health lab personnel in developing countries to establish a PCR diagnostic facility for efficient support to patient care as well as public health actions.
more
Drinking-water quality regulations and standards developed or revised in accordance with this guidance will reflect the best practices identified in the WHO Guidelines for Drinking-water Quality to most effectively protect public health. Moreover, the regulations and standards will consider local ne...eds, priorities and capacities to ensure that they are realistic and appropriate. Topics covered include:
- Guiding principles
- Getting started
- Selecting parameters and parameter limits
- Setting out compliance monitoring requirements
more
Program Report for Collaborative Agreement: DFD-A-00-08-00309-00 September 30, 2008 -December 31, 2015
Enfrentando la enfermedad de Alzheimer en los países en desarrollo.
Rev Neuropsiquiatr 80 (2), 2017 (P. 105-110)
Recibido: 03/02/2017 Aceptado: 12/06/2017
Cognitive deficits in schizophrenia can massively impact functionality and quality of life, furthering the importance of cognitive training. Despite the development of the field in Europe and in the United States, no programmes have been developed and tested in developing countries. Different cultur...al backgrounds, budget restrictions, and other difficulties may render treatment packages created in high income countries difficult for adoption by developing nations. We performed a pilot double-blind, randomized, controlled trial in order to investigate the efficacy and feasibility of an attention and memory training programme specially created in
a developing nation. The intervention used simple, widely available materials, required minimal infrastructure, and was conducted in groups.The sample included seventeen stable Brazilians with schizophrenia. Sessions were conducted weekly during five months. The cognitive training group showed significant improvements in inhibitory control and set-shifting over time. Both groups showed improvements in symptoms, processing speed, selective attention, executive function, and long-term visual memory. Improvements were found in the control group in long-term verbal memory and concentration. Our findings reinforce the idea that cognitive training in schizophrenia can be constructed using simple resources and infrastructure, facilitating its adoption by developing countries, and it may improve cognition.
more
With the growing prevalence of type 2 diabetes, particularly in emerging countries, its management in the context of available resources should be considered. International guidelines, while comprehensive and scientifically valid, may not be appropriate for regions such as Asia, Latin America or Afr...ica, where epidemiology, patient phenotypes, cultural conditions and socioeconomic status are different from America and Europe. Although glycaemic control and reduction of micro- and macrovascular outcomes remain essential aspects of treatment, access and cost are major limiting factors; therefore, a pragmatic approach is required in restricted-resource settings. Newer agents, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in particular, are relatively expensive, with limited availability despite potentially being valuable for patients with insulin resistance and cardiovascular complications. This review makes a case for the role of more accessible second-line treatments with long-established efficacy and affordability, such as sulfonylureas, in the management of type 2 diabetes, particularly in developing or restricted-resource countries.
more
1.Orthopedics - education 2.Prostheses and implants - utilization 3. Orthotic devices - utilization 4.Developing countries 5.Guidelines 6.Teaching materials I.World Health Organization II.International Society for Prosthetics and Orthotics